Interactions between raltegravir and Rifadin (rifampin)
rifampin and raltegravir (Moderate Drug-Drug)
MONITOR: Coadministration with potent inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 such as rifampin may reduce the plasma concentrations of raltegravir, which is primarily metabolized by UGT1A1-mediated glucuronidation. The impact of other inducers of drug-metabolizing enzymes (e.g., carbamazepine, phenytoin, phenobarbital) on UGT1A1 is unknown.
MANAGEMENT: Caution is advised when raltegravir is used in combination with potent UGT1A1 inducers such as rifampin.
